Vaccines

Steps toward improvement include more access to primary care.

BD says results could be available within two hours.

Abrupt cutoff ‘would create wide-ranging chaos’ in health care, White House says.

Attorneys general file petition to withdraw requirement.

Administration pushes for vaccines and boosters for the fall.

Agency seeks to reduce exposure risks as in-person schooling resumes

Study links discrepancy to adults’ misbeliefs about vaccine safety

Jason Lee, M.S., Ph.D.(c), and John J. Russell, M.D., discuss the future of influenza vaccination and provide key takeaways from the study.

Vaccine experts discuss coinfection with COVID-19 and influenza.

Jason Lee, M.S., Ph.D.(c), and John J. Russell, M.D., discuss the cost associated with influenza and how vaccination can provide cost savings.

AAFP president discusses endorsement, patient approaches, next round of shots.

Drs. Jason Lee and John J. Russell discuss the impact of chronic health conditions on adults.

Vaccine experts discuss racial disparities and the impact on influenza vaccinations.

Four for adult vaccines effective immediately, four pending approval for youths.

Jason Lee, M.S., Ph.D.(c), and John J. Russell, M.D., address vaccine hesitancy and gaps in influenza vaccines in adults.

Jason Lee, M.S., Ph.D.(c), discusses results and takeaways from the study of a high-dose influenza vaccine in older adults.

Company claims rivals copied proprietary mRNA technology to make shots.

Jason Lee, M.S., Ph.D.(c), discusses the rationale, objectives, and methods for a study of the efficacy and effectiveness of a high-dose influenza vaccine in older adults.

Jason Lee, M.S., Ph.D.(c), discusses the background to seasonal influenza.

Back-to-school season is prime time to reach parents and children about immunizations.

Codes enable billing for lab tests, administering vaccines

The pandemic underscored the incredible power of vaccination.

The move will delay the vaccine’s authorization for this younger group.

An EUA for the smaller shots would plug a hole in the nation’s vaccination strategy.

Spikevax is now the second COVID-19 vaccine approved by US regulators.

The company says a third dose of their COVID-19 vaccine is effective against the latest variant of the disease.

Nearly a third of hospital personnel had still not been vaccinated against COVID-19 by mid-September.

The move comes just in time for the holiday travel season.

The administration is also reportedly planning on purchasing millions of doses of the company’s antiviral pill.

The company is asking the FDA to make the additional shots available to anyone 18 years old or older.